ClinicalTrials.gg

Angelini Pharma clinical trials

Also known as ACRAF.

Part of Angelini Holding S.p.A., which holds 100% as of 2024-12-31. Source

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 60 studies whose lead sponsor is Angelini Pharma or one of 3 companies grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 13, 2026.

Our grouping of 4 registry names, not the registry’s. See them and correct one ↓

Pipeline: 2 programs

Each counted once: 2 with a study Angelini Pharma leads registered in the last two years.

  • Phase 3
  • Phase 4 (approved, new studies)

The 1 phase-3 program — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Angelini Pharma’s own registered studies; Angelini Pharma’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Angelini Pharma’s studies test, most studies first; none is open now — 10 drugs with a page of their own. Each count opens the studies in search.

Studies, none open

Coming up

1 of Angelini Pharma’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 1D
  3. J’27
  4. F
  5. M
  6. A
  7. M
  8. J
  9. J
  10. A
  11. S
  12. O
  13. N

Add it to your calendar (.ics) → With an account.

All 60 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now23%
  • Completed4880%
  • Stopped early813%
  • Status unknown or other23%Approved for marketing 1 · Status unknown 1

Phase

  • Phase 114
  • Phase 211
  • Phase 37
  • Phase 45

Where

  • Italy17
  • Switzerland14
  • Spain11
  • United States11
  • Poland8
  • Germany4

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 916
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 026

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Angelini Pharma.

  • Aziende Chimiche Riunite Angelini Francesco S.p.A
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    40 studies
  • Catalyst Pharmaceuticals, Inc.
    Acquired — became part of Angelini Pharma, Jul 15, 2026 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    13 studies →
  • Angelini Farmacéutica
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • Angelini Pharma Česká republika s.r.o.
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Studies

Recruiting first, then most recently updated. Showing 50 of 60. Browse all 60 →